Ferritin Levels in a Cohort of Affected Males of Mild Hemophilia A Carriers and Their Unaffected Siblings.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 4050-4050
Author(s):  
M. Kawaja ◽  
M.F. Scully ◽  
B. Barrett ◽  
M. Walsh ◽  
D. MacGregor

Abstract Iron deficiency is often used as a surrogate marker of bleeding. According to (multiple) studies, suboptimal iron stores can affect cognitive function, energy level and hence, quality of life. Due to a founder affect certain regions of the Canadian province of Newfoundland and Labrador have a very high prevalence of mild Hemophilia A. To accurately plan for future health related needs of these patients, a base-line cross-sectional study of a large cohort segregating a known founder mutation (Val2016Ala) was undertaken. Serum ferritin concentrations, complete blood counts (CBCs), menstrual blood loss assessed using Pictorial Blood Loss Assessment Chart (PBAC), bleeding histories, BMIs, and quality of life data using the SF-36 questionnaire were collected. Prevalence(%) of Suboptimal Iron Status for Women and Men Sub-Grouped By Menstrual Status and Mutation Status Serum Ferritin Cut-off(ug/L) **P Chi-Square <0.001 *P Chi-Square <0.01 Cohort <11 <24 <40 <50 Females(n=141) 12.1* 37.6** 55.3** 62.4** Males(n=77) 1.3* 4.1** 6.5** 6.5** Menstruating Women(n=81) 15.0 54.3** 71.6** 80.2** Non-Menstruating Women(n=58) 8.6 15.5** 31.0** 36.2** Menstruating Carriers(n=46) 8.7 50.0 65.2 73.9 Menstruating Controls(n=35) 23.5 60.0 80.0 88.6 Affected Males(n=46) 0.0 4.3 6.5 6.5 Control Males(n=31) 3.2 3.2 6.5 6.5 § Six women had hemoglobin concentrations less than 120 g/L and 11 men had concentrations less than 140 g/L, with anemia comparably observed in patients with or without the mutation(data not shown). Women in general reported a lower mean General Health Scale score (63.9, 59.9–67.9 vs. 70.6, 69.5–71.7) and a higher mean Role Emotional Scale score (89.3, 85.8–92.8 vs 79.5, 77.7–81.3) than norms for the general U.S. population. Men with a history of severe bleeding had significantly lower ferritin levels than men without a history of severe bleeding (123.4 g/L, 63.6–186.3 g/L, 105.9–301.5; p <0,05). Mutation status did not influence iron status in either sex or menstrual blood loss in women as measured by the PBAC. Serum ferritin level was not associated with PBAC score. Neither the means of the eight SF-36 domains, health transition scale, nor the two component summary measures were significantly lower for mildly iron-deficient or iron-deficient women. The SF-36 is a general measure of various quality of life domains and may not be sensitive enough to measure the effects iron deficiency could potentially have on women’s cognition and fatigue. A study using measures more sensitive to these affects would better investigate the impact of iron deficiency. Further research is also required to determine whether the low ferritin levels observed in women could possible be a result of inadequate dietary intake of iron or insufficient iron absorption in addition to menstrual blood loss.

2001 ◽  
Vol 4 (2) ◽  
pp. 197-206 ◽  
Author(s):  
Anne-Louise M Heath ◽  
C Murray Skeaff ◽  
Sheila Williams ◽  
Rosalind S Gibson

AbstractObjectiveTo investigate the role of blood loss and diet in the aetiology of mild iron deficiency (MID) in premenopausal New Zealand women. Mild iron deficiency was defined as low, but not necessarily exhausted, iron stores (i.e. serum ferritin <20 μg/L) in the absence of anaemia (i.e. haemoglobin ≥120 g/L).DesignCross-sectional study of a volunteer sample of premenopausal adult women. Information on habitual dietary intakes (using a specially designed and validated computerised iron food frequency questionnaire), health and demographic status, sources of blood loss (including menstrual blood loss estimated using a validated menstrual recall method), contraceptive use, height and weight, haemoglobin, serum ferritin and C-reactive protein were collected.SettingDunedin, New Zealand during 1996/1997.ParticipantsThree hundred and eighty-four women aged 18–40 years.ResultsThe characteristics that were associated with an increased risk of MID were: low meat/fish/poultry intake, high menstrual blood loss, recent blood donation, nose bleeds, and low body mass index. The protective factors included shorter duration of menstrual bleeding, and multivitamin–mineral supplement use in the past year.ConclusionsThere are a number of potentially modifiable factors that appear to influence risk of MID. Women with low menstrual blood loss may be able to decrease their risk of MID by increasing their meat/fish/poultry intake, while those with a higher menstrual blood loss may be able to decrease their risk by decreasing their menstrual blood loss, perhaps by changing their method of contraception. Women should be encouraged to maintain a healthy body weight, and those who choose to donate blood, or who experience nose bleeds, should have their iron stores monitored.


2020 ◽  
Vol 29 (10) ◽  
pp. 1292-1302
Author(s):  
Joaquim Calaf ◽  
María Jesús Cancelo ◽  
Mercedes Andeyro ◽  
Juan Manuel Jiménez ◽  
Josep Perelló ◽  
...  

The Lancet ◽  
1965 ◽  
Vol 286 (7409) ◽  
pp. 407-409 ◽  
Author(s):  
A. Jacobs ◽  
E.Blanche Butler

Genes ◽  
2022 ◽  
Vol 13 (1) ◽  
pp. 118
Author(s):  
Luis Alfredo Utria Acevedo ◽  
Aline Morgan Alvarenga ◽  
Paula Fernanda Silva Fonseca ◽  
Nathália Kozikas da Silva ◽  
Rodolfo Delfini Cançado ◽  
...  

Background: Hemochromatosis is a genetic condition of iron overload caused by deficiency of hepcidin. In a previous stage of this study, patients with suspected hemochromatosis had their quality of life (QL) measured. We observed that QL scores differed among genotypic groups of patients. In this reported final phase of the study, the aims were to compare QL scores after a treatment period of approximately 3 years and to analyze a possible association of the serum ferritin values with QL scores. Methods: Sixty-five patients were enrolled in this final phase and divided into group 1 (patients that showed primary iron overload and homozygous genotype for the HFE p.Cys282Tyr mutation) and group 2 (other kinds of genotypes). Short Form 36 (SF-36) was performed and consisted of eight domains with a physical and also a mental component. Results: Both groups had a significant decrease in serum ferritin concentrations: group 1 had a variation from 1844 ± 1313 ng/mL to 281 ± 294 ng/mL, and group 2 had a variation from 1216 ± 631 ng/mL to 236 ± 174 ng/mL. Group 1 had a smaller mean value for these six SF-36 domains compared with group 2, indicating a worse QL. Conclusions: In this final stage, six domains demonstrated a difference among genotypic groups (role emotional and mental health, adding to the four of the initial phase), reassuring the impact of the identified genotype on the QL of hemochromatosis patients. Furthermore, despite that both patient groups demonstrated similar and significant decreases in serum ferritin values, no association was found between the decrease in this biological parameter and the SF-36 domains.


GYNECOLOGY ◽  
2018 ◽  
Vol 20 (4) ◽  
pp. 4-8
Author(s):  
G E Chernuha ◽  
L M Ilina ◽  
I A Ivanov

Abnormal uterine bleeding (AUB) is one of the most common frequent reasons for contacting a gynecologist and conducting intrauterine interventions. AUB causes iron deficiency anemia and a decrease quality of life of women, which in turn is the reason of their social and clinical significance. Based on the analysis of literature and international data recommendations, the review outlines the basic principles of AUB diagnosis, non-hormonal and hormone therapy Advantages of continuous regimen for the administration of progestogens, in particular the LNG-IUS, and COCs containing estradiol valerate, to reduce menstrual flow blood loss are presented in the article. The need for a differentiated approach of choosing the therapy based on age, causes of bleeding, and balance benefits and risks of medicines.


2012 ◽  
Vol 8 (5) ◽  
pp. 503-511 ◽  
Author(s):  
Andrea S Lukes ◽  
Jeffrey Baker ◽  
Scott Eder ◽  
Tammie L Adomako

Aim: Excessive blood loss during menstruation is a major problem for women of reproductive age. Women who experience heavy menstrual bleeding (HMB) often present to physicians because of the subsequent negative impact HMB has on their daily lives and activities. The objective of this post-hoc analysis is to evaluate daily menstrual blood loss (MBL) in women with HMB and assess the relationship between daily MBL and women's perceptions of MBL, limitations in physical activities and limitations in social/leisure activities as measured by the Menorrhagia Impact Questionnaire. Materials & methods: Data from two randomized, placebo-controlled studies of an oral tranexamic acid formulation in women with HMB were assessed. Daily MBLs and Menorrhagia Impact Questionnaire scores were evaluated for two pretreatment cycles and the first three tranexamic acid treatment cycles of each study. Effect-size analyses were not conducted. Results & conclusion: Highest daily MBLs occurred on days 2 and 3 of menstrual cycles. Women's perceptions of daily MBL were consistent with objective measures of MBL. Higher daily MBL was related to increased limitations in physical activities and limitations in social/leisure activities. Daily MBL values were consistent with women's perceptions of MBL. Reduced daily MBL was associated with improvements in health-related quality of life.


2021 ◽  
Vol 8 ◽  
Author(s):  
Caterina Rizzo ◽  
Rosa Carbonara ◽  
Roberta Ruggieri ◽  
Andrea Passantino ◽  
Domenico Scrutinio

Iron deficiency (ID) is one of the most frequent comorbidities in patients with heart failure (HF). ID is estimated to be present in up to 50% of outpatients and is a strong independent predictor of HF outcomes. ID has been shown to reduce quality of life, exercise capacity and survival, in both the presence and absence of anemia. The most recent 2016 guidelines recommend starting replacement treatment at ferritin cutoff value &lt;100 mcg/l or between 100 and 299 mcg/l when the transferrin saturation is &lt;20%. Beyond its effect on hemoglobin, iron plays an important role in oxygen transport and in the metabolism of cardiac and skeletal muscles. Mitochondria are the most important sites of iron utilization and energy production. These factors clearly have roles in the diminished exercise capacity in HF. Oral iron administration is usually the first route used for iron repletion in patients. However, the data from the IRONOUT HF study do not support the use of oral iron supplementation in patients with HF and a reduced ejection fraction, because this treatment does not affect peak VO2 (the primary endpoint of the study) or increase serum ferritin levels. The FAIR-HF and CONFIRM-HF studies have shown improvements in symptoms, quality of life and functional capacity in patients with stable, symptomatic, iron-deficient HF after the administration of intravenous iron (i.e., FCM). Moreover, they have shown a decreased risk of first hospitalization for worsening of HF, as later confirmed in a subsequent meta-analysis. In addition, the EFFECT-HF study has shown an improvement in peak oxygen consumption at CPET (a parameter generally considered the gold standard of exercise capacity and a predictor of outcome in HF) in patients randomized to receive ferric carboxymaltose. Finally, the AFFIRM AHF trial evaluating the effects of FCM administration on the outcomes of patients hospitalized for acute HF has found significantly fewer hospital readmissions due to HF among patients treated with FCM rather than placebo.


Author(s):  
Susanne Macher ◽  
Cornelia Herster ◽  
Magdalena Holter ◽  
Martina Moritz ◽  
Eva Maria Matzhold ◽  
...  

Background: Besides anemia, iron deficiency may cause more subtle symptoms including those of the restless legs syndrome (RLS), the chronic fatigue syndrome (CFS) or sleeping disorders. Objective: The aim of this pre-planned secondary analysis was to compare the frequency and severity of symptoms associated with iron deficiency before and after (intravenous or oral) iron supplementation in iron deficient blood donors. Methods/Design: Prospective, randomized, controlled, single centre trial. (ClinicalTrials.gov: NCT01787526). Setting: Tertiary care center in Graz, Austria Participants: 138 female and 38 male whole blood and platelet apheresis donors aged &ge;18 and &le;65 years with iron deficiency (ferritin &le;30ng/ml at the time of blood donation). Interventions: Intravenous iron (1 g ferric carboxymaltose, n=86) or oral iron supplementation (10 g iron fumarate, 100 capsules, n=90). Measurements: Clinical symptoms were evaluated by a survey before iron therapy (visit 0, V0) and after 8-12 weeks (visit 1, V1) including questions about symptoms of RLS, CFS, sleeping disorders, quality of life and symptoms like headaches, dyspnoea, dizziness, palpitations, pica and trophic changes of fingernails or hair. Results: We found a significant improvement in the severity of symptoms for RLS, fatigue and sleep quality (p&lt;0.001). Furthermore, a significant decrease of headaches, dyspnoea, dizziness and palpitations was reported (p&lt;0.05). There was no difference between the type of iron supplementation (intravenous versus oral) and clinical outcome data. Conclusion: Iron supplementation in iron deficient blood donors may be an effective strategy to improve symptoms related to iron deficiency and the wellbeing of blood donors.


Sign in / Sign up

Export Citation Format

Share Document